BioLife Solutions, Inc. $BLFS Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. raised its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 2.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,967,518 shares of the medical equipment provider’s stock after buying an additional 70,248 shares during the quarter. Vanguard Group Inc. owned about 6.19% of BioLife Solutions worth $75,701,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of BLFS. Jacobs Levy Equity Management Inc. purchased a new stake in shares of BioLife Solutions in the 1st quarter valued at approximately $283,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of BioLife Solutions by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,422 shares of the medical equipment provider’s stock worth $489,000 after purchasing an additional 914 shares during the period. Jane Street Group LLC acquired a new stake in BioLife Solutions in the 1st quarter valued at approximately $1,091,000. Strs Ohio acquired a new stake in BioLife Solutions in the 1st quarter valued at approximately $153,000. Finally, Vestmark Advisory Solutions Inc. raised its position in BioLife Solutions by 160.3% in the second quarter. Vestmark Advisory Solutions Inc. now owns 24,438 shares of the medical equipment provider’s stock valued at $526,000 after purchasing an additional 15,049 shares during the period. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, Director Amy Duross sold 2,000 shares of the stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $24.60, for a total value of $49,200.00. Following the sale, the director owned 18,687 shares of the company’s stock, valued at $459,700.20. This trade represents a 9.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Troy Wichterman sold 990 shares of the business’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $25.59, for a total value of $25,334.10. Following the transaction, the chief financial officer directly owned 150,746 shares of the company’s stock, valued at approximately $3,857,590.14. This represents a 0.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 10,020 shares of company stock worth $241,593 in the last ninety days. 2.20% of the stock is owned by corporate insiders.

Trending Headlines about BioLife Solutions

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: Analyst/preview: Seeking Alpha highlights BioLife’s strategic refocus on core biopreservation media and vials, forecasting ~17–20% revenue growth in FY2026, positive GAAP net income and mid‑60s gross margins; cites the PanTHERA acquisition and a QKine partnership as drivers of higher ARPU and next‑gen product launches by late‑2026. BioLife Looks Strong For Fiscal Year 2026
• Positive Sentiment: Company presentation/press release: BioLife reiterated its growth and strategic refocus in a recent presentation, reinforcing management’s turnaround narrative and the FY26 outlook that underpins the Seeking Alpha preview. BioLife Solutions Highlights Growth and Strategic Refocus in Presentation
• Neutral Sentiment: Short‑interest data published for early March shows zero shares / 0.0 days‑to‑cover — this appears erroneous or non‑informative and does not indicate material short pressure at present. MarketBeat BLFS
• Negative Sentiment: Insider selling: Multiple senior executives (CFO, CMO, EVP, CTO and others) disclosed modest open‑market sales (hundreds of shares apiece at ≈$20.74). Amounts are small relative to their holdings, but clustered sales can trigger short‑term headline risk and investor caution. Insider trading alert

BioLife Solutions Trading Down 1.3%

Shares of NASDAQ BLFS opened at $19.86 on Friday. The stock has a market cap of $959.24 million, a P/E ratio of -180.53 and a beta of 1.90. The business’s fifty day simple moving average is $23.37 and its 200-day simple moving average is $25.07. BioLife Solutions, Inc. has a 12-month low of $19.10 and a 12-month high of $29.62.

Wall Street Analyst Weigh In

A number of research analysts have commented on BLFS shares. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, January 21st. Zacks Research raised BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 23rd. Northland Securities set a $34.00 target price on BioLife Solutions in a research note on Monday, January 5th. Wall Street Zen upgraded BioLife Solutions from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of BioLife Solutions in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, BioLife Solutions has an average rating of “Moderate Buy” and a consensus price target of $32.00.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.